Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Connect Biopharma Holdings Limited Market Cap
The Connect Biopharma Holdings Limited (CNTB) share price is expected to decrease by 15.41% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered CNTB. Price targets range from $0.82651 at the low end to $1.10202 at the high end. The current analyst consensus for CNTB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Connect Biopharma Holdings Limited has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Connect Biopharma Holdings Limited will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CNTB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Reiterates | Sep 6, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 13, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $8 | Maintains | Apr 17, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $7 | Initiates | Mar 4, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | $5 | Reiterates | Sep 13, 2023 |
| Thomas Smith SVB Leerink | Outperform | $7 | Maintains | Feb 8, 2023 |
| Louise Chen Cantor Fitzgerald | Overweight | $5 | Initiates | Jun 2, 2022 |
| Joseph Catanzaro Piper Sandler | Neutral | $1.5 | Downgrade | May 5, 2022 |
| Thomas Smith SVB Leerink | Outperform | $9 | Maintains | May 4, 2022 |
| Thomas Smith SVB Leerink | Outperform | $22 | Maintains | Jan 6, 2022 |
CICC | Outperform | Initiates | Jul 2, 2021 | |
Jefferies | Buy | Initiates | Apr 13, 2021 | |
SVB Leerink | Outperform | Initiates | Apr 13, 2021 |
When did it IPO
2020
Staff Count
81
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Barry D. Quart Pharm.D.
Market Cap
$59.7M
In 2023, CNTB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CNTB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 15 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Steven Chan has been appointed Chief Financial Officer of Attovia, bringing his expertise in finance leadership to the company.
Why It Matters - Steven Chan's appointment as CFO of Attovia signals potential strategic shifts and financial stability, which could positively influence investor confidence and stock performance.
Wed, 09 Oct 2024
Sentiment - NEGATIVE
Source - GuruFocus
Summary - Cone Biopharma (CNTB) shares fell 5.47% to $1.21, with a trading volume of 777 shares and no significant turnover rate.
Why It Matters - Cone Biopharma's 5.47% stock drop signals potential investor concerns about its performance or outlook, while low trading volume suggests limited market interest or confidence.
Wed, 02 Oct 2024
Sentiment - POSITIVE
Source - GuruFocus
Summary - Concordia Biotech (CNTB) stock rose 5.48% to $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%.
Why It Matters - Concordia Biotech's 5.48% price increase signals positive market sentiment, potentially indicating strong investor interest or favorable developments, impacting future trading momentum.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Connect Biopharma Holdings Limited reported its financial results for H1 2024, focusing on its commitment to treating inflammatory diseases. Further business updates were also provided.
Why It Matters - Connect Biopharma's financial results and business update signal its current performance and future prospects, impacting stock valuation and investor sentiment in the biopharmaceutical sector.
Mon, 01 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Connect Biopharma Holdings will host one-on-one investor meetings at the Leerink Partners I&I and Metabolism Therapeutics Forum on July 9-10, 2024, in Boston.
Why It Matters - Connect Biopharma's leadership meeting with investors at a key industry forum signals potential insights into their pipeline and strategic direction, impacting investor sentiment and stock performance.
Wed, 12 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Connect Biopharma Holdings appointed new leadership: Barry Quart as CEO, David Szekeres as President, and Kleanthis G. Xanthopoulos as Chair of the Board, enhancing its focus on therapies for chronic inflammatory diseases.
Why It Matters - New leadership at Connect Biopharma may signal strategic shifts or renewed focus, potentially impacting the company's direction, performance, and investor confidence in its clinical developments.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
